{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T14:43:46Z","timestamp":1779374626554,"version":"3.53.1"},"reference-count":153,"publisher":"Informa UK Limited","issue":"11","funder":[{"name":"no funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2020,11,1]]},"DOI":"10.1080\/14737140.2020.1822743","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T16:16:11Z","timestamp":1599840971000},"page":"965-983","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer"],"prefix":"10.1080","volume":"20","author":[{"given":"Mohamad","family":"Moussa","sequence":"first","affiliation":[{"name":"Head of Urology Department, Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G","family":"Papatsoris","sequence":"additional","affiliation":[{"name":"2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Dellis","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abou Chakra","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Department of Urology, Lebanese University, Beirut,Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajih","family":"Saad","sequence":"additional","affiliation":[{"name":"Head of Oncology Department, Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9,20]]},"reference":[{"issue":"8","key":"cit0001","volume":"96","author":"DeGeorge KC","year":"2017","journal-title":"Am Fam Physician"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2018.09.11"},{"issue":"2","key":"cit0003","volume":"29","author":"Un M","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1210"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1177\/107327481001700406"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2019.905"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.23736\/S0393-2249.18.03309-X"},{"issue":"6","key":"cit0008","first-page":"S199","volume":"3","author":"Zlotta AR","year":"2009","journal-title":"Can Urol Assoc J"},{"issue":"7","key":"cit0009","first-page":"423","volume":"69","author":"Gual Frau J","year":"2016","journal-title":"Arch Esp Urol"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2592-0"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000297"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1177\/1756287211431976"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14915"},{"issue":"3","key":"cit0014","volume":"6","author":"Soukup V","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"4","key":"cit0015","volume":"31","author":"Isharwal S","year":"2015","journal-title":"Indian J Urol"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2010.51.3.165"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.016"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.05.043"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.05.014"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02533-8"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.10.003"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13760"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0011"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.016"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1002\/9781118674826"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.028"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.4070"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-170118"},{"issue":"2","key":"cit0030","volume":"3","author":"Kamat AM","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.09.049"},{"issue":"3","key":"cit0032","volume":"4","author":"von Rundstedt FC","year":"2015","journal-title":"Transl Androl Urol"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000593"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.4103\/0970-1591.166446"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1517\/14656561003657145"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.04.031"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.066"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.2720"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1159\/000089164"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1159\/000090870"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604074"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2007.10.016"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24914"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8199"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283324d83"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1161"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.06.112"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0377-1"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.09.073"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.03.129"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.06.084"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.04.010"},{"issue":"4","key":"cit0053","volume":"162","author":"Luo Y","year":"1999","journal-title":"J Immunol"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2005.11.026"},{"issue":"5","key":"cit0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2010.06.147","volume":"184","author":"Nepple KG","year":"2010","journal-title":"J Urol"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.04.073"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07571.x"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2010.06.012"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2008.11.019"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00121"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0092-z"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00029"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2016.1155760"},{"issue":"1","key":"cit0064","volume":"75","author":"Tan WS","year":"2019","journal-title":"Eur Urol"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-009-0384-2"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.04.023"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1159\/000341912"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-180191"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5134-7"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000080568.91703.18"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1089\/089277903322518644"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.02.007"},{"issue":"6","key":"cit0073","volume":"165","author":"Waidelich R","year":"2001","journal-title":"J Urol"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0748-7"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1181-5"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03059"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0568-z"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04215.x"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0004-4"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26362"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00188"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00622"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01270"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02443-4"},{"issue":"4","key":"cit0085","volume":"71","author":"Barclay J","year":"2018","journal-title":"Arch Esp Urol"},{"key":"cit0086","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"Francisco LM","year":"2010","journal-title":"Immunol Rev"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs098"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0266-z"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6498-2"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22588"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003586"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9537"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102186"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S135157"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.7_suppl.350"},{"key":"cit0096","unstructured":"Merck Sharp & Dohme Corp. Efficacy and safety of pembrolizumab (MK-3475) in combination with bacillus Calmette-Guerin (BCG) in high-risk non-muscle invasive bladder cancer (HR NMIBC) (MK-3475-676\/KEYNOTE-676). NLM identifier: NCT03711032. [cited 2020 May 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03711032"},{"key":"cit0097","unstructured":"University of Oxford. Pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC) (PemBla). NLM identifier: NCT03167151. [cited 2020 May 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03167151"},{"key":"cit0098","unstructured":"National Cancer Institute (NCI). Atezolizumab in treating patients with recurrent BCG-unresponsive non-muscle invasive bladder cancer. NLM identifier: NCT02844816. [cited 2020 May 28]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02844816"},{"key":"cit0099","unstructured":"Roche H-L. Safety and pharmacology study of atezolizumab alone and in combination with bacille Calmette-Gu\u00e9rin (BCG) in high-risk non-muscle-invasive bladder cancer (NMIBC) participants. NLM identifier: NCT02792192. [cited 2020 May 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02792192"},{"key":"cit0100","unstructured":"Lee Moffitt H Cancer center and research institute. Phase 2 durvalumab (Medi4736) for bacillus calmette-gu\u00e9rin (BCG) refractory urothelial carcinoma in situ of the bladder. NLM identifier: NCT02901548. [cited 2020 May 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02901548"},{"key":"cit0101","unstructured":"Hellenic GenitoUrinary Cancer Group. Efficacy of durvalumab in non-muscle-invasive bladder cancer. NLM identifier: NCT03759496. [cited 2020 May 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03759496"},{"key":"cit0102","unstructured":"Noah Hahn MD. ADAPT-BLADDER: modern immunotherapy in BCG-relapsing urothelial carcinoma of the bladder. NLM identifier: NCT03317158. [cited 2020 May 29]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03317158"},{"key":"cit0103","unstructured":"Squibb B-M. A study of nivolumab or nivolumab plus experimental medication BMS-986205 with or without bacillus calumette-guerin (BCG) in BCG unresponsive bladder cancer that has not invaded into the muscle wall of the bladder (CheckMate 9UT). NLM identifier: NCT03519256. [cited 2020 May 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03519256"},{"key":"cit0104","unstructured":"University of Oklahoma. Avelumab plus bacille calmette-guerin (BCG) in patients with non-muscle invasive bladder cancer. NLM identifier: NCT03892642. [cited 2020 May 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03892642"},{"key":"cit0105","unstructured":"Institut Paoli-Calmettes. Bladder PREserVation by radiotherapy and immunotherapy in BCG unresponsive non-muscle invasive bladder cancer (PREVERT). NLM identifier: NCT03950362. [cited 2020 May 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03950362"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0291-4"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2285"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2017.07.004"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0094-9"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.11.012"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00151"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9602"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1817"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0504-7"},{"key":"cit0115","unstructured":"Altor BioScience. A study of ALT-801 in patients with bacillus calmette-guerin (BCG) failure non-muscle invasive bladder cancer. NLM identifier: NCT01625260. [cited 2020 May 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01625260"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7470"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096705"},{"key":"cit0118","unstructured":"Altor BioScience. QUILT-3.032: A multicenter clinical trial of intravesical bacillus calmette-guerin (BCG) in combination with ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer. NLM identifier: NCT03022825. [cited 2020 May 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03022825"},{"key":"cit0119","first-page":"117","volume":"6","author":"Lee J","year":"2018","journal-title":"J Immunother Cancer Suppl"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.7.4.543"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0126"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2014.314"},{"issue":"2","key":"cit0123","volume":"19","author":"Cardillo MR","year":"2000","journal-title":"J Exp Clin Cancer Res"},{"key":"cit0124","unstructured":"National Cancer Institute (NCI). Study of bacillus calmette-guerin (BCG) combined with PANVAC versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least 1 course of BCG. NLM identifier: NCT02015104. [cited 2020 May 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02015104"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00195"},{"issue":"4","key":"cit0126","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-14-0015","volume":"2","author":"Chiocca EA","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.05.027"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.03.030"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5300-6"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.3064"},{"key":"cit0131","unstructured":"FKD Therapies Oy. INSTILADRIN\u00ae in patients with bacillus calmette-guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). NLM identifier: NCT02773849. [cited 2020 May 31]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02773849"},{"key":"cit0132","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/404581"},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1059"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.07.097"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.07.005"},{"key":"cit0136","volume":"5","author":"Sverrisson EF","year":"2013","journal-title":"Res Rep Urol"},{"key":"cit0137","volume":"4","author":"Kowalski M","year":"2010","journal-title":"Drug Des Devel Ther"},{"key":"cit0138","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.07.020"},{"key":"cit0139","unstructured":"Viventia Bio. Vicinium treatment for subjects with non-muscle invasive bladder cancer previously treated with BCG. NLM identifier: NCT03258593. [cited 2020 June 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02449239"},{"key":"cit0140","unstructured":"National Cancer Institute (NCI). Durvalumab and vicinium in subjects with high-grade non-muscle-invasive bladder cancer previously treated with bacillus calmette-guerin (BCG). NLM identifier: NCT03258593. [cited 2020 June 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03258593"},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030755"},{"key":"cit0142","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-160056"},{"key":"cit0143","unstructured":"Aadi LLC Phase 1\/2 study of ABI-009 in nonmuscle invasive bladder cancer. NLM identifier: NCT02009332. [cited 2020 June 1]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02009332"},{"key":"cit0144","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-170095"},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.1593\/neo.07178"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2267"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2015.03.003"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33253-w"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1038\/srep27232"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.09.109"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-160084"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1016697"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1265720"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2020.1822743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T14:05:14Z","timestamp":1620482714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2020.1822743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,20]]},"references-count":153,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,1]]}},"alternative-id":["10.1080\/14737140.2020.1822743"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2020.1822743","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}